Leaf curl syndrome of pigeonpea (Cajanus cajan (L.) Millsp.) is a systemic response to effective nodulation by the Rhizobium strain IC3342

Rhizobium str. IC3342 is an unusual bacterium that causes a leaf curl syndrome in pigeonpea. Growth characteristics, plasmid profile, conserved nif and nod gene sequences and nodulation host range of this strain resemble that of the fast-growing Rhizobium str. ANU240 (NGR234). Leaf curl occurred only in hosts effectively nodulated. A plasmid-cured, non-nodulating derivative failed to induce leaf curl symptoms. The str. IC3342 competed poorly with fast- and slow-growing root-nodule bacteria, but the observed nodule occupancy of 10% was enough to produce leaf curl symptoms. Suppression of nodule development by added inorganic nitrogen also prevented symptom expression. Approach grafting of a healthy pigonpea plant with leaf curl symptoms resulted in the development of leaf curl symptoms on the growing shoots of the healthy plant within 8 days of graft union. Further symptom expression ceased after graft separation. Feeding xylem sap from the leaf curled plant to a healthy plant induced the initial symptom of the syndrome, bending of the growing leaf tip. It is concluded that leaf curl induction is a systemic response for which effective nodulation is an apparent prerequisit

Translocation of zeatin riboside and zeatin in soybean explants

Soybean explants consisting of a leaf, one or more young pods, and a subtending piece of stem were given a 1-h pulse of 3 H (ring-labeled)-zeatin riboside (ZR) or -zeatin (Z), via the base of the stem, followed by a 24-h incubation. At the end of the pulse, about 55% of the soluble 3 H was in the leaf blades, 11% in the petiole, 30% in the stem, 2% in the carpels, 0.1% in the seed coats, and 0.08% in the embryos. After 24 h, the percentages were 58, 7, 26, 6, 2, and 0.3, respectively. During this period, the total soluble 3 H decreased by 84%, the remainder being bound to “insoluble” material. The 3 H-cytokinin was rapidly converted to diverse metabolites including adenosine and adenine. At the end of the 1-h pulse, appreciable percentages (1–16%) of the total soluble 3 H in the seed coats chromatographed with ZR (or dihydro ZR) and with the 5′-phosphate of ZR, but these percentages declined markedly at 24 h. No distinct peaks of 3 H corresponded to known metabolites in the soluble extracts of embryos, and at 24 h, the 3 H equivalent to ZR must have been less than 0.0006% of the 3 H-ZR supplied. The bound 3 H corresponded to adenine and guanine in DNA and RNA. In contrast to cytokinin, 3 H-adenosine given as a pulse was readily translocated into the seed coats and embryos. Thus, cytokinin (ZR and Z) flowing up through the xylem from the root system does not readily enter the embryo (though metabolites such as adenosine could), and the seeds clearly do not compete with the leaves for this supply of cytokinin.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45929/1/344_2005_Article_BF02042255.pd

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016